To look at the differences in "social cognition"- the ability to look at the interpret the social world and put yourself in someone else's shoes - between people with depression, people with frontotemporal dementia and healthy controls.
The purpose of this study is to assess the safety, tolerability, biomarker and cognitive efficacy of investigational products in subjects who are known to have, or are at risk of having an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive impairment and improves disease-related biomarkers.
This study also offers an observational component collecting cognitive assessment data until the availability of an enrolling drug treatment group, referred to as cognitive run-in (CRI).
The purpose of this study is to provide subjects who have completed participation in a Phase 2 or Phase 3 trial with TRx0237 continued access to therapy and to evaluate the long-term safety of TRx0237.
The purpose of this study is to determine the clinical, cognitive, motor, brain imaging, genetic and biochemical biomarker characteristics of Alzheimer disease (AD), subcortical vascular disease (SVaD) and mixed dementia (AD + sVaD).